Eli Lilly and Co
LLY1071.390USD
-5.090-0.47%
Fechamento 12/23, 16:00（ET）Cotações atrasadas em 15 min
1.01TValor de mercado
52.28P/L TTM
Mais detalhes de Eli Lilly and Co Empresa
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Informações de Eli Lilly and Co
Código da empresaLLY
Nome da EmpresaEli Lilly and Co
Data de listagemJul 09, 1970
CEORicks (David A)
Número de funcionários47000
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 09
EndereçoLilly Corporate Ctr
CidadeINDIANAPOLIS
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal46285
Telefone13172762000
Sitehttps://www.lilly.com/
Código da empresaLLY
Data de listagemJul 09, 1970
CEORicks (David A)
Executivos da empresa Eli Lilly and Co
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+0.93%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
Outro
3.42B
21.95%
Por RegiãoUSD
Nome
Receita
Proporção
U.S.
10.81B
69.51%
Europe
2.57B
16.55%
Other foreign countries
1.18B
7.60%
Japan
521.00M
3.35%
China
465.90M
2.99%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
Outro
3.42B
21.95%
Distribuição de ações
Atualizado em: qua, 12 de nov
Atualizado em: qua, 12 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
Outro
68.21%
Investidores
Investidores
Proporção
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
Outro
68.21%
Tipos de investidores
Investidores
Proporção
Investment Advisor
45.37%
Investment Advisor/Hedge Fund
18.69%
Foundation
9.75%
Research Firm
2.04%
Pension Fund
1.89%
Bank and Trust
1.84%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
Outro
16.91%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lilly Endowment, Inc.
95.49M
10.09%
-243.99K
-0.25%
Sep 30, 2025
The Vanguard Group, Inc.
80.05M
8.46%
+1.17M
+1.49%
Jun 30, 2025
PNC Investments LLC
51.08M
5.4%
-9.49K
-0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.30M
4.36%
-168.44K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
34.51M
3.65%
+69.02K
+0.20%
Jun 30, 2025
Capital Research Global Investors
20.76M
2.19%
+5.01M
+31.81%
Jun 30, 2025
Fidelity Management & Research Company LLC
24.36M
2.57%
-2.82M
-10.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.13M
1.92%
-397.62K
-2.15%
Jun 30, 2025
Capital World Investors
17.63M
1.86%
-748.08K
-4.07%
Jun 30, 2025
Wellington Management Company, LLP
13.99M
1.48%
+1.28M
+10.09%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
Ver Mais
VanEck Pharmaceutical ETF
Proporção47.56%
iShares U.S. Pharmaceuticals ETF
Proporção25.23%
Harbor Health Care ETF
Proporção18.24%
Roundhill GLP-1 & Weight Loss ETF
Proporção16.7%
Health Care Select Sector SPDR Fund
Proporção14.06%
Proshares Ultra Health Care
Proporção13.57%
iShares U.S. Healthcare ETF
Proporção13.54%
Amplify Weight Loss Drug & Treatment ETF
Proporção11.93%
Fidelity MSCI Health Care Index ETF
Proporção11.73%
Goldman Sachs Future Health Care Equity ETF
Proporção10.84%
Dividendo
Um total de
18.06B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Eli Lilly and Co?
Os cinco principais acionistas de Eli Lilly and Co são:
Lilly Endowment, Inc. detém 95.49M Ações, representando 10.09% do total de Ações.
The Vanguard Group, Inc. detém 80.05M Ações, representando 8.46% do total de Ações.
PNC Investments LLC detém 51.08M Ações, representando 5.40% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 41.30M Ações, representando 4.36% do total de Ações.
State Street Investment Management (US) detém 34.51M Ações, representando 3.65% do total de Ações.
Lilly Endowment, Inc. detém 95.49M Ações, representando 10.09% do total de Ações.
The Vanguard Group, Inc. detém 80.05M Ações, representando 8.46% do total de Ações.
PNC Investments LLC detém 51.08M Ações, representando 5.40% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 41.30M Ações, representando 4.36% do total de Ações.
State Street Investment Management (US) detém 34.51M Ações, representando 3.65% do total de Ações.
Quais são os três principais tipos de acionistas de Eli Lilly and Co?
Os três principais tipos de acionistas da Eli Lilly and Co são:
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
Quantas instituições possuem ações da Eli Lilly and Co (LLY)?
Em 2025Q3, 5762 instituições possuíam ações da Eli Lilly and Co, com valor de mercado aproximado de 789.85M, representando 83.53% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em -0.75%.
Qual é a maior fonte de receita da Eli Lilly and Co?
Em FY2025Q2, o segmento de negócios Diabetes-Mounjaro gerou a maior receita para Eli Lilly and Co, totalizando 5.20B e representando 33.42% da receita total.
